Featured Research

from universities, journals, and other organizations

Diabetic Hearts Feel The Burn

Date:
November 26, 2007
Source:
Journal of Clinical Investigation
Summary:
A normal heart burns both fats and sugars for fuel. In contrast, diabetic hearts rely almost exclusively on fats for energy, leading to heart failure. PPAR-alpha and PPAR-beta/delta are proteins found in heart tissue. In the diabetic heart, enhanced activity of PPAR-alpha drives the use of fats as fuel, but the role of PPAR-beta/delta has been unknown.

A normal heart burns both fats and sugars for fuel. In contrast, diabetic hearts rely almost exclusively on fats for energy, leading to heart failure. PPAR-alpha and PPAR-beta/delta are proteins found in heart tissue.

In the diabetic heart, enhanced activity of PPAR-alpha drives the use of fats as fuel, but the role of PPAR-beta/delta has been unknown. While seeking to understand the role of these proteins in diabetic heart failure, Daniel Kelly and his colleagues at Washington University School of Medicine, Missouri, have discovered that selective activation of PPAR-beta/delta in the heart improves cardiac function in mice.

The heart of mice in which PPAR-alpha is engineered to be overexpressed only in the heart (MHC-PPAR-alpha mice) has been shown to mimic the diabetic heart -- with increased fat and decreased sugar fuel usage, and subsequent cardiac arrest.

In contrast, in this study, the hearts of mice engineered to overexpress PPAR-beta/delta only in the heart (MHC-PPAR-beta/delta mice) were shown to process sugars for energy and had function normally.

Most strikingly, the degree of heart tissue death following heart attack was reduced in MHC-PPAR-beta/delta mice compared with both normal mice and MHC-PPAR-alpha mice.

Researchers also uncovered a reason for these observed differences -- the two proteins have opposite effects on the genes responsible for sugar usage by the heart for fuel. The authors therefore suggested that heart-specific PPAR-beta/delta activation might be a useful therapy for reducing diabetes-induced heart disease in humans.

Journal article: Nuclear receptors PPAR-beta/delta and PPAR-alpha direct distinct metabolic regulatory programs in the mouse heart, Journal of Clinical Investigation, November 21, 2007


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Cite This Page:

Journal of Clinical Investigation. "Diabetic Hearts Feel The Burn." ScienceDaily. ScienceDaily, 26 November 2007. <www.sciencedaily.com/releases/2007/11/071121172254.htm>.
Journal of Clinical Investigation. (2007, November 26). Diabetic Hearts Feel The Burn. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2007/11/071121172254.htm
Journal of Clinical Investigation. "Diabetic Hearts Feel The Burn." ScienceDaily. www.sciencedaily.com/releases/2007/11/071121172254.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins